Sharda Cropchem Limited

Tel.: +91 22 66782800 FAX: +91 22 66782828 / 66782808 E-mail: office@shardaintl.com

E-mail : office@shardaintl.com
Regd. Office : Prime Business Park, Dashrathlal Joshi Road, Vile Parle (W),

Mumbai - 400056, India. www.shardacropchem.com





30th October, 2025

To,

National Stock Exchange of India	BSE Limited
Limited	Phiroze Jeejeebhoi Tower,
Exchange Plaza, 5th Floor, Plot No.	Dalal Street,
C/1,	Mumbai – 400 001
G-Block, Bandra Kurla Complex,	
Bandra (E), Mumbai – 400 051	
Trading Symbol: SHARDACROP	Scrip Code: 538666

Subject: <u>Investors / Analyst's Presentation for the Quarter and half year ended</u> 30th September, 2025.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing herewith the presentation to be made to the Investors/Analysts on the Financial Results of the Company for the quarter & half year ended 30th September, 2025.

The presentation is also being uploaded on the website of the Company www.shardacropchem.com in accordance with Regulation 46 of the Listing Regulations.

We request you to take the same on record.

Yours Sincerely,

Jetkin Gudhka Company Secretary & Compliance Officer

Encl.: As above



GROWING STRONGER, GOING FURTHER.

SAFE HARBOR





This presentation has been prepared by and is the sole responsibility of **Sharda Cropchem Limited** (the "Company"). By accessing this presentation, you are agreeing to be bound by the trailing restrictions.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer or recommendation to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment thereof. In particular, this presentation is not intended to be a prospectus or offer document under the applicable laws of any jurisdiction, including India. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. There is no obligation to update, modify or amend this communication or to otherwise notify the recipient if the information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Certain statements contained in this presentation that are not statements of historical fact constitute "forward-looking statements." You can generally identify forward looking statements by terminology such as "aim", "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "objective", "goal", "plan", "potential", "project", "pursue", "shall", "should", "will", "would", or other words or phrases of similar import. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or other projections. Important factors that could cause actual results, performance or achievements to differ materially include, among others: (a) our ability to successfully implement our strategy, (b) our growth and expansion plans, (c) changes in regulatory norms applicable to the Company, (d) technological changes, (e) investment income, (f) cash flow projections, and (g) other risks.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes.



About Sharda Cropchem Limited



"We are a fast-growing global agrochemicals company with a peer position in the generic crop protection chemicals industry. Our vast and growing library of dossiers and IPRs provide us solid foundations for growth in the global marketplace, especially in Advanced Markets such as Europe, North America and Latin America. It equips us with the ability to operate in a diversified range of formulations and generic active ingredients space globally"

AGROCHEMICAL FOCUSED COMPANY

Sharda Cropchem is an Intellectual Property (IP) driven company engaged in marketing and distribution of wide range of formulations and generic active ingredients



Asset Light Business Model: Efficiently channelizing time and resources for strengthening core competency of identifying generic molecules and registration opportunities which offer scalable growth with limited capital requirements



Large Pipeline of Registrations*: Procured 2,994 registrations. Additionally, it has filed 1,068 applications for registrations globally pending at different stages



Diversified Sourcing Arrangements: Enduring relationship with multiple manufacturers and formulators enables to source and supply formulations or generic active ingredients at competitive prices



Consistently Increasing Global Presence: With diversified range of product portfolio, Company has grown by expanding business operations in 80+ countries, across Europe, NAFTA, Latin America and ROW



Widespread Distribution Network: Presence in the entire agrochemical value chain with 525 third party distributors and 500+ sales force serving the Company's esteemed clientele in 80+ countries

*As on 30th September 202

Company's apt domain knowledge and experience gives substantial competitive advantage for expanding business in existing markets and new geographies

ASSET LIGHT BUSINESS MODEL





Overall Agrochemical Value Chain

Sharda's Operating Area









Basic & Applied Research

Identification

Registration

Active Ingredient Manufacturing

Formulation & Packaging

Marketing & Distribution

Focus on identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulations through third-party distributors and/or own sales force

Manufacturing of Als and formulations is outsourced

Acts as a key differentiator from an innovator company, allowing the Company to save its capital, time and resources on R&D

Highly flexible operating model resulting in :

- Overall cost competitiveness
- Efficient management of fluctuating market demand across various geographies
- Offering wide range of formulations and Als

INCREASING GLOBAL PRESENCE WITH WIDESPREAD DISTRIBUTION





Presence

80+ countries

across Europe, NAFTA, LATAM & RoW Global Resource Deployment

500+



Distributors

525+

CAPEX incurred in H1 FY26

Rs. 250 Cr.

Over the years, the Company has built a strong brand franchise within our global markets; we are benefiting through the economies of scale in our portfolio and leveraging value of our supply chain to deliver value to our customers across geographies

In addition to newer markets, the wide global presence has allowed us to find new, specialised sales and local marketing talent.

Successfully adopted a factory-tofarmer approach to become a onestop solution provider to our global customers Strengthening and widening the sales force in Europe, USA, Canada, Mexico, Colombia, South Africa, India, and rest of the world, in addition to third party distributors with a goal to enhance its presence in the agrochemical value chain

It enables the Company to penetrate its formulations and generic active ingredients in various countries backed by the third-party distributors and presence of its own sales force

Company has gained a great deal from globalization, including new customers and diverse geocentric revenue streams. Over the years, we have mastered flexibility and adopted innovative ways to grow our business overseas

The Sharda Advantage Healthy Wide Product Relationships with Global Reach Suppliers Range One Stop Solution Quality with Faster Sales **Provider for Crop** Affordability Service **Care Products**

WAY FORWARD





Forward Integration - Build Sales Force

- ✓ Leverage market presence and execution capabilities
- ✓ Adopt the factory to farmer approach and be a one stop solution provider
- ✓ Strategy on ground in different regions of NAFTA, Europe, LATAM and other key markets in ROW



2

Expand & Strengthen Distribution Presence

- ✓ Expand geographical reach using existing library of dossiers
- ✓ Two-fold strategy of further penetrating existing markets and entering new markets

3

Continual Investment in Product Registrations

- ✓ Continue to identify generic molecules going off patent
- ✓ Investing in preparing dossiers and seeking registrations in own name

4

Focus on Operational Efficiencies


- ✓ Accelerated focus on revenue generating investments
- ✓ Margin improvements
- ✓ Better cost management and eliminate NVAs

INDUSTRY OUTLOOK & GROWTH DRIVERS





Global crop protection (In Billion USD) – CAGR of 3.96%



Source: Annual Report (FY25)

INDUSTRY DRIVERS

A Growing Population: Global population is projected to rise from 7.6 Bn in 2025 to 8.6 Bn by 2030 and 9.8 Bn by 2050 placing unprecedented pressure on global food and protein systems

A growing middle class fuels demand for increased food and protein production, which in turn drives demand for grain to support growth

Fewer arable acres per capita means that products need to continue to maximise farmer yields; arable land is expected to decrease from half an acre per person today to less than one-third of an acre per person by 2050

Experienced Management









Mr. Ramprakash V. Bubna

Chairman & Managing Director

- ✓ Holds a Bachelor's Degree of Technology in Chemical Engineering from IIT, Bombay
- ✓ He has over 57 years of experience in chemicals, agrochemicals and related businesses
- ✓ He is responsible for the Company's overall business operations and strategy

Mr. Ashish Bubna

Whole Time Director

- ✓ Holds a Bachelor's Degree in Commerce from the University of Mumbai
- ✓ Over 34 years of experience in marketing of chemicals, agrochemicals and related businesses.
- ✓ Instrumental in strategizing early investment in product registrations and building the library of product dossiers.
- ✓ Responsible for marketing, procurement, registrations and logistics functions of the agrochemical business.

Mr. Manish Bubna

Whole Time Director

- ✓ Holds a Bachelor's Degree in Chemical Engineering from the Department of Chemical Technology, Bombay University.
- ✓ Over 32 years of experience in chemicals, agrochemicals and related businesses
- ✓ Spearheaded the Company's foray into the conveyor belt and general chemicals business
- ✓ Also oversees the information technology, logistics and documentation functions of the Company




Q2 FY26 Financial Highlights

Q2 FY26: SEGMENT WISE HIGHLIGHTS








Q2 FY26: PRODUCT WISE HIGHLIGHTS (Agrochemical Segment)





₹ Cr.



Insecticides

Fungicides

TOTAL REVENUES (Agrochemical Segment)

57%

54%

21%


27%


22%


19%


100%


100%













Q2 FY26: REGION WISE BREAKUP (Agrochemical Segment)





Q2 FY26: REGION WISE BREAKUP (Non - Agrochemical Segment)







Q2 FY26: FINANCIAL HIGHLIGHTS





₹ Cr.





Profit After Tax

- ✓ Revenue in Q2 FY26 increased by 20% primarily driven by high volume growth of ~35%. We saw volume growth across all regions
- ✓ Agrochemical volumes grew by 36.1% in Q2 FY26
- ✓ Non-Agrochemical volumes grew by 10.9% in Q2 FY26

- ✓ Gross Margins have improved 690 basis points to 34.5%. These margins are expected to remain at these levels in FY26 supported by lower input costs and improved price realizations
- ✓ EBITDA for the quarter grew by 71% to Rs. 139 crores with EBITDA Margins at 15% showcasing improvement by 450 bps as compared to Q2 FY25
- ✓ PAT for the quarter grew by 75% to Rs. 74 crores as compared to Rs. 42 crores in Q2 FY25




H1 FY26 Financial Highlights

H1 FY26: SEGMENT WISE HIGHLIGHTS








H1 FY26: PRODUCT WISE HIGHLIGHTS (Agrochemical Segment)





₹ Cr.



Insecticides

Fungicides

TOTAL REVENUES (Agrochemical Segment)

52%

52%

22%

26%


27%

23%


% of Revenue


100%


100%












H1 FY26: REGION WISE BREAKUP (Agrochemical Segment)






H1 FY26: REGION WISE BREAKUP (Non - Agrochemical Segment)

H1 FY25





H1 FY26



H1 FY26

19

H1 FY25

% of Revenue


H1 FY26


H1 FY25


H1 FY26: FINANCIAL HIGHLIGHTS












- ✓ Revenue in H1 FY26 increased by 23% primarily driven by higher volume growth of 24%. We saw volume growth across all regions, with Europe being the key contributor
- ✓ Agrochemical volumes grew by 23.4% in H1 FY26
- ✓ Non-Agrochemical volumes grew by 31.2% in H1 FY26

- ✓ Gross Margins have increased to 35.0% and it is expected to remain in the similar range for FY26
- ✓ EBITDA for the half year stood at Rs. 281 crores as compared to Rs. 167 crores in H1 FY25, a growth of 69%
- ✓ PAT for H1FY26 stood at Rs. 217 crores as compared to of Rs. 70 crores in H1 FY25, a growth of 212%

STRONG BALANCE SHEET







Total Equity

Rs. **2,676** crores*

Rs. 2,501 crores as on Mar'25

Cash, Bank & Liquid Investments

Rs. **794** crores*

Rs. 558 crores as on Mar'25

^{*} ROCE = EBIT / Average Capital Employed; RoE = PAT / Average Equity (On TTM Basis)

^{*} As on 30th September 2025



Annexure

Q2 & H1 FY26 FINANCIAL HIGHLIGHTS





Particulars	Q2 FY26	Q2 FY25	Y-o-Y	H1 FY26	H1 FY25	Y-o-Y
Revenue from Operations	929.1	776.9	20%	1,913.9	1,562.0	23%
COGS	608.4	562.2		1,244.0	1,118.4	
Gross Profit	320.7	214.7	49%	669.9	443.6	51%
Gross Margin %	34.5%	27.6%		35.0%	28.4%	
Employee Expenses	12.3	10.4		27.3	21.5	
Other Expenses	169.5	123.0		361.5	255.4	
EBITDA	138.9	81.3	71%	281.1	166.7	69%
EBITDA Margin %	15.0%	10.5%		14.7%	10.7%	
Forex (Gain)/Loss	6.1	(19.4)		(67.0)	(11.1)	
Depreciation	76.2	69.1		154.3	133.9	
Other Income	29.4	14.4		61.9	33.7	
EBIT	86.1	46.0	87%	255.8	77.5	230%
EBIT Margin %	9.3%	5.9%		13.4%	5.0%	
Finance Cost	0.3	0.5		0.9	1.2	
РВТ	85.7	45.5	88%	254.9	76.3	234%
Tax Expense	11.4	3.1		37.7	6.6	
PAT	74.4	42.4	75%	217.2	69.7	212%
PAT Margin %	8.0%	5.5%		11.3%	4.5%	
Earnings Per Share (EPS) In Rs.	8.24	4.70		24.06	7.72	

BALANCE SHEET



₹ Cr.



EQUITY & LIABILITIES Sep-25 Mar-25 Equity Equity share capital 90.2 90.2 2,585.2 Other equity 2,410.3 Equity attributable to equity holders of the Company 2,675.5 2,500.6 0.5 0.4 Non-controlling interests **Total Equity** 2,675.9 2,501.0 Non-current liabilities Financial liabilities Lease liabilities Other financial liabilities 30.6 63.0 **Provisions** 0.3 1.3 Deferred tax liabilities (net) 172.4 173.8 Total non-current liabilities 203.3 238.1 **Current liabilities** Financial liabilities Borrowings Lease liabilities 4.0 7.8 Trade payables total outstanding dues of micro enterprises and small 3.2 5.1 enterprises other than micro enterprises and small enterprises 1,320.2 1.305.1 Other financial liabilities 538.5 501.3 Other current liabilities 77.3 104.7 75.7 57.6 Provisions 4.9 4.2 Current tax liabilities **Total current liabilities** 2,023.9 1,985.7 4,903.1 4,724.9 **Total Equity & Liabilities**

ASSETS	Sep-25	Mar-25
Non-current assets		. 10.1 _0
Property, plant and equipment	2.9	3.0
Right to use assets	3.6	7.2
Intangible assets	810.8	740.2
Intangible assets under development	291.6	291.4
Financial assets	291.0	291.4
	100.0	- A
Other Financial Assets	122.3	5.4
Other non-current assets	18.4	16.4
Income tax assets (net)	32.7	63.4
Deferred Tax Assets	16.4	11.6
Total non-current assets	1,298.6	1,138.5
Current assets		
Inventories	1,418.9	971.9
Financial assets		
Investments	554.7	294.3
Trade receivables	1,233.2	1,955.4
Cash and cash equivalents	165.3	127.2
Bank balance other than cash and cash equivalents	62.5	93.1
Loans	-	-
Other financial assets	22.2	47.5
Other current assets	147.7	96.8
Total current assets	3,604.5	3,586.4
Total Assets	4,903.1	4,724.9

CASH FLOW STATEMENT






		; ·
Particulars	H1 FY26	H1 FY25
Profit Before Tax	254.9	76.3
Adjustments	126.5	100.6
Operating profit before working capital changes	381.4	176.9
Changes in working capital	229.0	321.6
Cash generated from operations	610.3	498.5
Direct taxes paid (net of refund)	(5.2)	(40.8)
Net Cash from Operating Activities	605.2	457.8
Net Cash from Investing Activities	(523.8)	(329.3)
Net Cash from Financing Activities	(59.3)	(34.5)
Exchange difference arising on conversion (debited) / credited to foreign currency translation reserve	11.9	14.0
Net Change in cash and cash equivalents	34.0	108.0
Opening Cash Balance	127.2	87.3
Effect of exchange rate changes on cash & cash equivalents held in foreign currencies	4.1	0.7
Closing Cash Balance	165.3	196.1

KEY FINANCIAL PERFORMANCE INDICES









^{*} EBITDA is excluding IA & IAUD write-off

29

[^] Total Cash & Cash Equivalents (Includes FDs of Rs. 128 crores clubbed in Non Current Other Financial Assets)

HISTORICAL PROFIT & LOSS





Particulars	FY25	FY24	FY23	FY22	FY21
Revenue from Operations	4,319.9	3,163.0	4,045.2	3,579.8	2,395.6
COGS	3,028.1	2,342.4	2,860.8	2,499.8	1,636.0
Gross Profit	1,291.8	820.6	1,184.4	1,080.0	759.7
Gross Margin %	29.9%	25.9%	29.3%	30.2%	31.7%
Employee Expenses	52.0	42.4	44.8	44.2	37.3
Other Expenses	626.3	494.9	438.9	336.4	305.5
EBITDA*	681.6	318.1	712.6	728.6	455.2
EBITDA Margin %	15.8%	10.1%	17.6%	20.4%	19.0%
Forex (Gain)/Loss	17.9	0.4	57.6	16.5	-19.9
Depreciation	274.7	267.1	248.1	245.3	170.4
Other Income	59.5	59.8	40.3	28.9	45.9
EBIT	380.4	75.5	435.3	466.5	312.2
EBIT Margin %	8.8%	2.4%	10.8%	13.0%	13.0%
Finance Cost	2.1	3.6	4.5	2.2	2.8
РВТ	378.3	71.9	430.7	464.2	309.5
Tax Expense	73.9	40.0	88.8	115.0	80.2
PAT	304.4	31.9	342.0	349.3	229.2
PAT Margin %	7.0%	1.0%	8.5%	9.8%	9.6%
Earnings Per Share (EPS) In Rs.	33.74	3.53	37.90	38.71	25.40

^{*} EBITDA is excluding IA & IAUD write-off

BALANCE SHEET - EQUITY & LIABILITIES





Equities & Liabilities	FY25	FY24	FY23	FY22	FY21
Shareholder's Funds					
Equity and Share Capital	90.2	90.2	90.2	90.2	90.2
Other Equity	2,410.4	2,146.9	2,141.8	1,822.2	1,524.1
Non-controlling Interest	0.4	0.4	0.4	0.3	0.3
Total Equity	2,501.0	2,237.5	2,232.4	1,912.8	1,614.6
Non-Current Liabilities					
Borrowings	-	-	-	-	-
Trade Payables	-	_	-	2.4	2.4
Lease Liabilities	-	7.8	-	3.5	8.4
Other Financial Liabilities	63.0	58.4	1.7	1.6	3.2
Provisions	1.3	1.4	2.7	2.3	3.0
Deferred Tax Liabilities (net)	173.8	152.8	143.4	128.9	92.9
Total Non-Current Liabilities	238.1	220.3	147.9	138.6	109.9
Current Liabilities			<u>:</u>		
Borrowings	-	3.4	3.0	38.0	67.8
Lease Liabilities	7.8	7.2	0.0	5.1	4.5
Trade Payables	1,310.2	921.2	1,377.6	1,177.6	806.8
Other Financial Liabilities	501.3	502.5	431.4	324.8	149.1
Other Current Liabilities	104.7	69.0	78.1	55.4	58.0
Current Tax Liabilities	4.2	1.5	61.4	4.2	3.2
Provisions	57.6	76.0	19.1	86.7	50.0
Total Current Liabilities	1,985.7	1,580.5	1,970.6	1,691.8	1,139.4
Total Equity & Liabilities	4,724.9	4,038.3	4,350.8	3,743.1	2,863.9

BALANCE SHEET - ASSETS





ASSETS	FY25	FY24	FY23	FY22	FY21
Assets					
Non-Current Assets					
Property, Plant and Equipment	3.0	3.8	5.0	14.4	20.9
Right to Use Assets	7.2	14.4	0.0	-	-
Goodwill	0.0	0.0	0.0	0.0	0.4
Other Intangible assets	740.2	690.0	663.0	577.4	523.1
Intangible assets under development	291.4	282.9	203.9	212.2	131.0
Deferred Tax Assets (net)	11.6	10.3	7.9	4.9	6.0
Non-Current Tax Assets	63.4	72.1	72.3	71.6	73.6
Other financial assets	5.4	5.3	120.7	11.2	9.4
Other Non Current Assets	16.4	21.7	19.9	0.0	0.0
Total Non-Current Assets	1,138.5	1,100.4	1,092.7	891.7	764.5
Current Assets					
Inventories	971.9	991.6	1,134.3	892.8	525.5
nvestments	294.3	158.9	31.9	134.4	83.0
Trade Receivables	1,955.4	1,498.0	1,833.3	1,540.0	1,162.6
Cash & Cash equivalents	127.2	87.3	176.4	56.7	85.6
Other Bank balances	93.1	0.6	0.2	109.3	175.0
Loans	0.0	0.0	0.0	0.5	-
Other Financial Assets	47.5	128.1	5.5	48.9	28.1
Other Current Assets	96.8	73.4	76.5	68.9	39.6
Total Current Assets	3,586.4	2,937.9	3,258.2	2,851.5	2,099.3
Total Assets	4,724.9	4,038.3	4,350.8	3,743.1	2,863.9

CSR ACTIVITIES



CSR initiatives taken up by the Company are in the areas of Promoting Education, Healthcare, Eradicating Hunger, Empowerment of Women, Animal Welfare, Promotion of Sports and Rural Development Projects

Promoting Education







Animal Welfare





Medical Aid & Relief

'मरीजों की देखभाल सच्चा परमार्थ'

राज्यपाल कोश्यारी ने युवाओं में बढ़ते नशा पर जताई चिंता

■ प्रसं, मुंबई : राज्यपाल भगत सिंह कोश्यारी ने मरीजों की देखभाल को सच्चा परमार्थ बताते हुए कहा कि अगर लोग टीबी के मरीजों को गोद लें और देश को टीबी मुक्त बनाने के लिए मरीजों के पोषण आहार के खर्च का वहन करें, तो यह भी दान होगा। इस दौरान उन्होंने युवाओं में तंबाकू के साथ नशे की बढ़ती प्रवृति पर चिंता जताई। वह परमार्थ रत्न पुरस्कार समारोह में बोल रहे थे।

सामाजिक संस्था परमार्थ सेवा समिति की तरफ से राजभवन में आयोजित पुरस्कार और दीपावली स्नेह कार्यक्रम का आयोजन किया गया था। इसर्प राज्यपाल के हाथों टाटा मेमोरियल अस्पताल के निदेशक डॉ. राजेंद्र बडवे और उप निदेशक डॉ. शैलेश श्रीखंडे को कैंसर के इलाज, सर्जरी और अनुसंधान में उनके उल्लेखनीय कार्य के लिए परमार्थ रत्न पुरस्कार से सम्मानित किया गया। साथ ही, अविनाश साबले को परमार्थ खेल रत्न पुरस्कार से सम्मानित किया गया। साथ

शहराकरण के साथ बढ़ रहा कैंसर: डॉ.राजेंद्र बडवे ने कहा कि भारत



में कैंसर की दर पश्चिमी देशों की तुलना में कम है, यह संतोष की बात है। लेकिन, देश में बढ़ते शहरीकरण के साथ कैंसर की दर बढ़ रही है। अगर 2035 तक तंबाकू की खेती पूरी तरह से बंद कर दी जाए, तो बड़े पैमाने पर कैंसर को नियंत्रित किया जा सकता है, क्योंकि कुल कैंसर रोगियों में से तंबाकू के सेवन से होने वाले कैंसर रोगियों की संख्या 40 प्रतिन त है। संस्था अध्यक्ष मनमोहन गोयनका ने संस्था की अगर से किए जा रहे कार्यों की रूपरेखा

रखा। संस्था क चयरमन लक्ष्मानाथवण बियानी ने 18 मंजिला कीमोथेरेपी सेंटर टाटा मेमोरियल हाँस्पिटल को बनाकर दान में देने की घोषणा की। इस अवसर पर महिला समिति की अध्यक्षा शारदा रामप्रकाश बूबना, बजरंगलाल तापड़िया, महाबीरप्रसाद तापड़िया, ज्योतिप्रसाद तापड़िया, दिलीप पिरामल, रवि लालपुरिया, कैलाश अग्रवाल, रमेश पोद्दार सहित बड़ी संख्या में लोग उपस्थित थे।



GROWING STRONGER, GOING FURTHER.

THANK YOU

Company: Sharda Cropchem Limited



Sharda Cropchem Limited

CIN: L51909MH2004PLC145007

Mr. Shailesh Mehendale - CFO

cfo@shardaintl.com / finance@shardaintl.com

Tel: +91 22 6678 2800

Investor Relation Advisors: Strategic Growth Advisors Pvt. Ltd.

 $SGA \underline{^{Strategic\ Growth\ Advisors}}$

CIN: U74140MH2010PTC204285

Mr. Deven Dhruva / Ms. Jinal Shah

deven.dhruva@sgapl.net/jinal.shah@sgapl.net

Tel: +91 98333 73300 / +91 97692 69759